



(Adapted from BCCDC Communicable Disease Control Varicella Guideline June 2018)

TABLE OF CONTENTS

1.0	AUTHORITY	2
2.0	GOAL	2
3.0	EPIDEMIOLOGIC FEATURES OF VARICELLA ZOSTER INFECTION	2
4.0	CASE IDENTIFICATION	3
4.1	National Case Definition for Varicella.....	3
5.0	CASE MANAGEMENT	4
5.1	Laboratory Testing	4
5.1.1	Virus Identification	5
5.1.2	Serology.....	5
5.2	Case Treatment	6
5.3	Future Immunization of the Case.....	7
5.4	Case Isolation in the Community	7
5.5	Exclusion of Cases in the Community	7
5.5.1	Exclusion from School and Child Care.....	7
6.0	CONTACT MANAGEMENT	8
6.1	Types of Exposures Warranting Consideration	8
6.2	Assessment of Susceptibility Among Exposed Contacts	9
7.0	IMMUNOPROPHYLAXIS OF SUSCEPTIBLE CONTACTS	10
7.1	Varicella Zoster Immune Globulin (Varlg)	11
8.0	REPORTING	11
9.0	CLINICAL DESCRIPTION.....	12
9.1	Vaccine-Modified Disease.....	13
9.2	Differential Diagnosis of Varicella	13
10.0	EPIDEMIOLOGY OF VARICELLA IN YUKON.....	14
11.0	VARICELLA IMMUNIZATION IN YUKON.....	14
12.0	REFERENCES	14
13.0	CONTACT INFORMATION.....	16

1.0 AUTHORITY

Yukon Public Health and Safety Act (2009). Available at www.gov.yk.ca/legislation/legislation/page_p.html

2.0 GOAL

The goal of the Yukon varicella control program is to reduce the mortality and morbidity associated with varicella disease. This will be accomplished through routine childhood immunization, immunization of susceptible adults and promotion of appropriate measures for high-risk susceptible individuals following exposure to varicella.

3.0 EPIDEMIOLOGIC FEATURES OF VARICELLA ZOSTER INFECTION

Mode of transmission: person-to-person by direct contact, airborne spread of vesicle fluid of skin lesions of acute varicella and herpes zoster, or infected secretions of the respiratory tract of varicella cases that also might be aerosolized; indirectly by articles freshly contaminated with respiratory secretions or vesicle fluid of such cases.

Incubation period: 10-21 days, commonly 14-16 days. May be as long as 28 days in individuals who receive varicella zoster immune globulin post exposure, and may be shorter in immunodeficient individuals.

Period of communicability: generally from 1-2 days before onset of rash and until all lesions are crusted (usually 5 days following rash onset). May be prolonged in immunocompromised people. Those with zoster lesions are infectious while rash is vesico-pustular (usually 7-10 days).

4.0 CASE IDENTIFICATION

4.1 National Case Definition for Varicella

Surveillance	Definition	Reportable to YCDC
Confirmed Case	Clinical evidence of illness ¹ and laboratory confirmation of infection: <ul style="list-style-type: none"> • detection of VZV DNA by real-time polymerase chain reaction (RT-PCR) from an appropriate clinical specimen OR <ul style="list-style-type: none"> • isolation or direct antigen detection of varicella-zoster virus (VZV) from an appropriate clinical specimen OR <ul style="list-style-type: none"> • molecular nucleic acid testing (NAT) for central nervous system infection from an appropriate clinical specimen (CSF or brain biopsy) OR <ul style="list-style-type: none"> • seroconversion or a significant rise (e.g., fourfold or greater) by any standard serologic assay in varicella-zoster IgG titre between acute and convalescent sera OR Clinical evidence of illness ¹ in a person with an epidemiologic link to a laboratory-confirmed case of chickenpox or zoster infection	No
Probable case	Clinical evidence of illness ¹ in the absence of laboratory confirmation and epidemiologic link to a laboratory-confirmed case.	No

¹ Clinical illness is characterized by a rash with rapid evolution of macules to papules, vesicles, and crusts; all stages are simultaneously present; lesions are superficial and may appear in crops. Breakthrough disease (varicella in a previously immunized person) is usually mild with less than 50 skin lesions, and of shorter duration; the rash may contain few or no vesicles. See [section 9.1](#) for further details.

Practice Point

Report all **high risk** and **susceptible contacts** of a confirmed case to YCDC as soon as possible due to the Post Exposure Prophylaxis (PEP) requirements. Refer to [section 6.1](#) and [6.2](#).

5.0 CASE MANAGEMENT

Case management is conducted by the health care provider as appropriate.

5.1 Laboratory Testing

With the decline in incidence of varicella, and milder cases in previously immunized individuals, fewer clinicians have experience with natural infection and the clinical diagnosis is less reliable.

Testing of varicella cases: laboratory confirmation of varicella should be sought in all cases of suspect or clinically diagnosed varicella, including in previously immunized persons. This is because clinical diagnosis is now less reliable given the declining rates of varicella.

For those with recent varicella containing vaccination, and a varicella like illness, varicella-like rash that occurs greater than 2 weeks **and** less than 42 days after immunization is generally due to vaccine.

Varicella like illness that occurs either within 2 weeks of varicella containing vaccine **or** more than 42 days post immunization is more likely due to wild type VZV and should therefore be tested for VZV.

Varicella disease in individuals who have received varicella vaccine is referred to as vaccine modified disease. In general vaccine modified disease is associated with a significantly reduced number of lesions (< 50 lesions and little or no fever) and is not generally associated with secondary transmission. Those presenting with varicella like illness **and more than 50 lesions** in the window between 7 to 42 days of immunization with a varicella-containing vaccine should therefore be tested for VZV (see [Section 9.1](#) for further details).

In cases of suspected secondary transmission, testing should similarly be conducted in those with a varicella-like illness with 50 or more lesions with onset within 7 to 42 days of immunization with a varicella-containing vaccine.

Testing of zoster cases: Testing for suspected cases of zoster should only be undertaken when the case is:

- being considered for antiviral treatment
- under 19 years of age
- previously immunized against varicella and has no prior history of varicella disease
- a health care worker/ student
- a pregnant woman at term

Diagnostic testing is preferably through virus identification. Specimens should be submitted with a completed [Virology Requisition](#), Herpes Viruses–skin swab for varicella-zoster.

5.1.1 Virus Identification

PCR is the most reliable method for confirming varicella infection.

The most appropriate clinical specimen will usually be vesicular fluid, scabs or cells from the base of a lesion collected within the first 3 days of the rash.

Specimen collection for intact vesicles

Collection is performed using a conventional sterile swab or 25 ga. syringe, and virus transport medium:

- Unroof the blister with a tuberculin syringe needle or broken edge of a sterile swab shaft.
- Swab the base of the broken blister firmly, applying enough pressure to collect epithelial cells without causing bleeding. Place the swab in transport media and transport to the laboratory.
- Alternatively the contents of the vesicular lesion may be aspirated with the syringe and transferred to the vial of transport medium

Other specimen types

For some disease presentations with a suspected VZV etiology (e.g., meningitis, multi-focal organ damage), samples of cerebral spinal fluid (CSF), blood or biopsy tissue may also be shipped.

5.1.2 Serology

Serology is discouraged for confirmation of acute varicella unless virologic testing cannot be done e.g., because scabs have all dried and crusted.

Diagnostic testing of acute varicella by varicella IgM is not available in Yukon/BC. This is because testing using commercial kits for IgM antibody lacks sensitivity and specificity; false-positive IgM results are common in the presence of high IgG levels, and results are unreliable.

If acute and convalescent sera are to be collected for varicella diagnosis by IgG rise, the acute serum should be collected within 7 to 10 days of rash onset, and the convalescent serum should be collected at least 7 to 14 days (preferably 2 to 3 weeks) later.

While serial testing of IgG antibody titres to diagnose acute infection can be done, this is not the preferred method of diagnosis for a number of reasons:

- results will not be available in a timely fashion
- serology will not allow for differentiation between wild type and vaccine virus, which may be relevant in specific clinical situations
- a 4-fold rise in IgG antibody may not be observed in vaccinated individuals.

Interpretation of serological results:

After a primary infection, both IgG and IgM antibodies develop within 3-7 days after rash onset. Both antibodies then increase reaching a plateau 2-3 weeks later. Antibody levels may be reported as Non-Reactive (no detectable antibody), Indeterminate (the level of antibody detected is considered borderline reactive or equivocal) or Reactive (antibody is detectable within the positive range of the assay).

Non-Reactive and indeterminate levels of IgG antibodies may be observed in the acute stage of infection rising to reactive levels in subsequent weeks. In the absence of acute infection, indeterminate levels of IgG may represent very low levels of antibody many years after initial infection or vaccination.

If the acute blood sample shows low reactive, indeterminate or non-reactive IgG results, then a convalescent sample should be collected. Recent infection is confirmed if a significant rise in antibody levels is observed between acute and convalescent sera.

5.2 Case Treatment

The decision by a clinician to use antiviral therapy including the route and duration of treatment is determined by host factors (e.g., immunocompromised), extent of infection and the initial response to treatment. In the immunocompetent host, most viral replication has stopped within 72 hours of rash onset and the American Academy of Pediatrics Red Book Committee does not recommend antiviral treatment in otherwise healthy children with varicella.

Antivirals should be considered, however, for those at moderately increased risk of complications including otherwise *healthy but unimmunized people aged older than 12 years, and for pregnant women*. Treatment is recommended within 24-48 hours of rash onset.

For information regarding communicability and symptom management, direct client to HealthLinkBC [File #44a Facts about Chickenpox](#).

Use of acetylsalicylic acid (ASA, e.g., Aspirin®) should be avoided in children and adolescents under 19 years old with chickenpox in order to avoid Reye Syndrome.

5.3 Future Immunization of the Case

Defer all immunizations with live and inactivated vaccines until at least four weeks after illness onset in the case. This is because varicella infection is accompanied by abnormalities of cell-mediated immunity (CMI).

People who have had laboratory confirmed varicella after the age of 1 year are considered immune against varicella, and should be exempt from future varicella immunization, with their infection documented in their immunization record. Infants who develop varicella in the first year of life should be immunized against varicella with two doses, beginning as early as the first birthday, because varicella in infancy may not confer protection..

5.4 Case Isolation in the Community

Cases should avoid attending new settings during their communicable period to avoid infecting new contacts. They should avoid air travel, visiting hospitalized individuals, swimming, and especially contact with infants, susceptible pregnant women and susceptible immunocompromised individuals.

5.5 Exclusion of Cases in the Community

5.5.1 Exclusion from School and Child Care

Most authorities recommend that children with varicella who are well enough to participate in regular activities may continue to attend school or day care regardless of the state of the rash. This is because varicella is infectious prior to development of the rash during the prodromal stage, and contacts are likely to have been exposed prior to the diagnosis.

When staff or health care providers become aware of a case in a school or childcare setting, they should notify YCDC. YCDC will ensure notification of school administrators.

On a case by case basis, parents/guardians of immunocompromised susceptible children may consult their health care provider about self-exclusion from settings where an infectious case is in attendance, or where susceptible contacts have been exposed and may be incubating varicella infection.

6.0 CONTACT MANAGEMENT

6.1 Types of Exposures Warranting Consideration

The priority for contact follow-up is identification of those **susceptible contacts at high risk for complications of varicella disease**.

See [section 3.0](#) for information about mode of transmission, incubation period, and period of communicability.

Significant exposure: The following types of contact are considered significant if exposure has occurred during a case's period of communicability. This includes the following type of source case: *active primary varicella, or a zoster case prior to or within 24 hours of onset of antiviral treatment if disseminated or in an immunocompromised host.*

- continuous household contact (living in the same dwelling)
- being indoors (e.g., classroom, doctor's waiting room) for more than 1 hour
- sharing the same hospital room for more than 1 hour or having more than 15 minutes of face-to-face contact
- touching the lesions or articles freshly soiled by discharge from vesicles of a person with active varicella or zoster (shingles).

Practice Point

The following is **not** considered an exposure: contact with an immunocompetent person whose non-disseminated zoster lesions are well covered by clothing or dressings.

Dried scabs from varicella-zoster lesions are not infective.

Interval to infectiousness for susceptible exposed individuals:

Susceptible persons should be considered potentially infectious 8-21 days following exposure to a varicella case (up to 28 days if they receive Varlg).

Individuals at high risk for complications of varicella disease are:

- those who are immunocompromised due to disease or therapy
- premature infants less than 37 weeks gestation exposed during their first weeks of life
- newborns whose mothers develop varicella disease 5 days before to 48 hours after delivery, or whose mothers have active zoster lesions in an area that cannot be covered (e.g., lower buttocks) at the time of parturition
- pregnant women
- those with cystic fibrosis
- candidates or recipients of a solid organ transplant or haematopoietic stem cell transplant (HSCT)
- those undergoing hemo- or peritoneal dialysis
- those with nephrotic syndrome
- those on chronic salicylate therapy.

6.2 Assessment of Susceptibility Among Exposed Contacts

Serological testing to establish immunity among exposed contacts is not practical and not necessary in most individuals. Healthy susceptible contacts who have uncertain history of prior varicella or prior immunization against varicella should be offered 2 doses of varicella vaccine without prior testing for immunity.

Serological testing for immunity may need to be conducted in exposed individuals without a history of prior varicella disease and without records of varicella vaccine receipt if they are pregnant women or health care workers.

Consider as immune the following:

Healthy individuals who are contacts of a case:

Self-reported history or physician diagnosed varicella after the age of 1 constitute 'proof of immunity' only if the episode occurred PRIOR to 2004²

OR

laboratory proven diagnosis of prior varicella or zoster after the age of 1

OR

documented receipt of 2 doses of varicella containing vaccine

OR

serological proof of immunity³ (at any time in the past).

High risk contacts of a case (refer to section 6.1):

Serological proof of immunity³ (at any time in the past)

OR

documented receipt of 2 doses of varicella containing vaccine EXCEPT

HSCT recipients, who should be considered susceptible even if previously immunized or had disease if they are post transplantation, unless they have been immunized post transplantation.

² Children and adolescents recorded in the immunization registry as exempt from varicella vaccine due to 'prior disease' should be considered immune for all practical purposes. Requirements for specific individuals may be more stringent e.g., for health care workers, and serological proof of immunity may be requested.

³ Serology (IgG) should be used for testing for immunity, although it is most reliable for this purpose in individuals with wild type immunity, and is less sensitive in the detection of vaccine-derived immunity.

Consider as susceptible the following:

Any person with one of the following should be considered varicella susceptible:

- history of varicella illness before the 1st birthday without subsequent immunization with 2 doses of varicella-containing vaccine
- no or uncertain history of two doses of varicella vaccine given after the 1st birthday
- history of varicella or herpes zoster in/ after 2004 at the time of the disease episode without laboratory confirmation
- non-immune VZV IgG serology
- an individual within the post HSCT period regardless of a history of varicella or positive serologic test results pre-transplant

Note: Adults who have emigrated from tropical/subtropical areas are less likely to have acquired chickenpox in childhood and are more often susceptible to VZV than those who grew up in temperate climates. There is evidence that this may be less true for those who lived in urban settings.

7.0 IMMUNOPROPHYLAXIS OF SUSCEPTIBLE CONTACTS

Post-exposure immunoprophylaxis includes varicella vaccine to those without contraindications to vaccine receipt, or varicella zoster immune globulin (VarIlg) to high risk susceptible individuals (as below).

Healthy susceptible contacts with an uncertain or incomplete history of prior varicella vaccine receipt should be offered up to 2 doses of varicella vaccine without prior testing for immunity.

Varicella vaccination has been shown to be effective in preventing or reducing the severity of varicella if given to a susceptible individual within 3 to 5 days after exposure to wild-type varicella. Post-exposure vaccination should be given as soon as possible after exposure but vaccination is still indicated 5 or more days post-exposure because it induces protection against subsequent exposures. There is no evidence that administration of varicella vaccine during the presymptomatic or prodromal stage of illness increases the risk of adverse events following immunization or more severe natural disease..

7.1 Varicella Zoster Immune Globulin (Varlg)

Varicella zoster immune globulin is only recommended for the following susceptible high risk persons following a significant exposure to varicella-zoster, and in whom receipt of varicella vaccine is contraindicated:

- Immunocompromised clients (congenital or acquired) due to treatment or disease including some clients receiving high doses of corticosteroids;
- Newborn infants whose mothers develop varicella disease 5 days before to 48 hours after delivery or have active zoster lesions to which the newborn may have been exposed;
- Infants and children in neonatal or pediatric intensive care settings, as determined by infectious disease/infection control specialist;
- Haematopoietic stem cell transplant recipients;
- Varicella-susceptible pregnant women; and
- Varicella-susceptible HIV-infected persons.

Varlg should be administered as soon as possible following exposure, and ideally within 96 hours after first exposure for maximal benefit. Administration more than 96 hours after exposure is of uncertain benefit; at this late stage, it may attenuate but not prevent disease. It may be given if less than 10 days have elapsed since the last exposure.

If a second varicella exposure occurs more than 3 weeks after a dose of Varlg, another dose of Varlg should be given.

Varlg can be only accessed for post exposure prophylaxis with the authorization of the MOH/YCDC. The Whitehorse General Hospital is the sole location storing Varlg for the territory.

Whitehorse

Monday – Friday, 0830 to 1630 hrs, if Varlg is indicated, YCDC will notify the WGH Lab (867-393-8739) and arrange for administration to occur in the WGH ER.

After hours, the MOH will call the WGH Laboratory at 393-8739 and make arrangements for administration.

Communities

Monday to Friday, 0830 to 1630 hrs, if Varlg is indicated, YCDC will notify the WGH Laboratory (867-393-8739) and arrange for the product to be shipped to the requesting Community Health Centre or hospital. See above for after hours.

8.0 REPORTING

Varicella (chickenpox) including vaccine-modified varicella, and zoster (shingles), are not currently reportable in Yukon. Numerous provinces and territories in Canada do not routinely report varicella disease. Beginning in 2019, varicella disease was removed from Yukon's Reportable Disease List. Only high risk and susceptible contacts are to be reported to YCDC in order to ensure prompt PEP management.

9.0 CLINICAL DESCRIPTION

Varicella zoster virus (VZV) is a DNA virus of the herpes virus family. It causes two diseases: varicella (chickenpox), the primary infection, and herpes zoster (shingles), a secondary infection due to a reactivation of latent varicella infection in the dorsal root ganglia.

Chickenpox typically affects children under the age of 10 years; 5-10% of the population remain susceptible to the disease in adulthood. The estimated average lifetime risk of reactivation as zoster/shingles is 28% and can occur at any time, most often after 60 years of age.

Chickenpox is manifested as a generalized, itchy rash that progresses quickly from macules to papules to vesicular lesions before crusting. The rash usually appears first on the head, next on the trunk and then on the extremities. Successive crops of lesions appear over several days, with different stages of maturity present at the same time. Healthy children usually have 250-500 lesions. A mild prodrome including fever and malaise may precede the rash.

In shingles, vesicles with an erythematous base appear in crops in irregular fashion on the surface of the skin innervated by a specific nerve. Severe pain and paresthesia are common.

Complications are more frequent in adolescents, adults, immunocompromised persons and pregnant women. Severe disease, disseminated varicella, and zoster are more likely to develop in immunocompromised persons. The complications of chickenpox include secondary bacterial skin and soft tissue infections, otitis media, bacteremia, pneumonia, osteomyelitis, septic arthritis, endocarditis, necrotizing fasciitis, toxic shock-like syndrome, hepatitis, thrombocytopenia, cerebellar ataxia, and encephalitis. Herpes zoster may result in permanent neurological damage such as cranial nerve palsy or visual impairment after zoster ophthalmicus. The most common debilitating complication of zoster is postherpetic neuralgia, defined as pain that persists after resolution of the zoster rash. This pain may last a year or longer after the episode of zoster. Incidence of postherpetic neuralgia increases with age.

The incidence of congenital varicella syndrome among infants born to mothers with varicella is approximately 2% when infection occurs between 13 and 19 weeks of gestation. The syndrome is rare when infection occurs before the 13th or after the 20th week. Congenital varicella syndrome results in a wide clinical spectrum, which may include low birth weight, ophthalmic abnormalities, skin scarring, limb atrophy, cerebral atrophy and other anomalies.

Infants exposed to varicella zoster virus in utero during the second 20 weeks of pregnancy can develop inapparent varicella and subsequent zoster early in life without having had extrauterine varicella.

Varicella infection can be fatal for an infant if the mother develops varicella from 5 days before to 2 days after delivery. When varicella develops in a mother more than 5 days before delivery and gestational age is 28 weeks or more, the severity of disease in the newborn is modified by

transplacental transfer of VZV-specific maternal IgG antibody.

The case fatality rates for varicella are highest among adults (30 deaths/100,000 cases), followed by infants under one year of age (7 deaths/100,000 cases.) While complications are more frequent in adolescents than in children, the case fatality rates are lowest in the 1-19 years age group (1-1.5 deaths/100,000 cases).

9.1 Vaccine-Modified Disease

Vaccine modified disease is defined as a varicella infection occurring after exposure to wild-type virus, more than 42 days following vaccination.

Varicella vaccine is not 100% effective, but a single dose of the vaccine prevents 95% of severe disease. Individuals who develop varicella after vaccination usually have mild disease ("vaccine-modified infection"). Individuals typically develop fewer than 50 skin lesions that are more commonly atypical, with papules that do not progress to vesicles.

Individuals with vaccine-modified infection experience a shorter duration of illness and lower incidence of fever than those with natural infection who were not vaccinated.

Approximately 25%-30% of vaccine-modified infections are not mild, with clinical features more similar to those in unvaccinated children.

There have been varying estimates of the rate of vaccine-modified disease. In the U.S., during a ten-year surveillance period (1995-2004) the rate of vaccine-modified disease was 9.5%. The severity and incidence of vaccine-modified disease among vaccinees increased with the time since vaccination.

Both primary and secondary vaccine failures can occur. Following vaccination there is waning immunity over time, and less opportunity to boost immunity through circulating VZV because of declining chickenpox rates.

9.2 Differential Diagnosis of Varicella

The differential diagnosis of varicella-like illness includes other viral exanthems, disseminated herpes simplex (especially in the immunocompromised host or neonate), and atypical zoster. Enteroviral infections can cause papulovesicular lesions that occur on the palms and soles, with vesicular lesions on the buccal mucosa. Impetigo can result in erythematous macules which progress to vesiculopustular lesions that dry and crust. Exposed areas such as the face, neck, and limbs are often involved, and group A Streptococcus is usually the etiologic agent.

10.0 EPIDEMIOLOGY OF VARICELLA IN YUKON

The epidemiology of varicella in Yukon has dramatically changed, with a large decrease in varicella incidence since the introduction of the publicly funded varicella vaccine in 2007. Between 2013 and 2018, a six-year period, 4 confirmed cases of varicella were reported.

11.0 VARICELLA IMMUNIZATION IN YUKON

Varicella immunization began in 2007 for infants ages 6-23 months via one dose. The routine 2-dose immunization program was introduced in 2012, where the first dose was offered at 12 months of age and the second dose at school entry (4-6 years). There was no formal catch-up schedule. In 2015, MMRV was added, for school entry only, as a second dose for children ages 4 to 6.

12.0 REFERENCES

Advisory Committee on Immunization Practices. Prevention of Varicella. Morb Mortal Wkly Rep (MMWR). 2007;56(RR-4):1-48. Available at www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html

American Academy of Pediatrics. Varicella-Zoster Virus Infections. In: Red Book: Report of the Committee on Infectious Diseases. 30th Edition. Elk Grove Village, IL. 2015. p. 846-860.

Brisson M, Edmunds WJ, Law B et al. Epidemiology of varicella zoster infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305-314.

Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine- Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington

D.C. Public Health Foundation. 2015. Also known as The Pink Book, available at www.cdc.gov/vaccines/pubs/pinkbook/

Chaves SS, Garguillo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007;356:1121-9. DOI: 10.1056/NEJMoa064040.

Health Canada. Infection Control Guidelines. Prevention and Control of Occupational Infections in Health Care. Canada Communicable Disease Report. 2002;28S1:128-139. Available at www.phac-aspc.gc.ca/publicat/ccdr-rmtc/02vol28/28s1/

Heymann, David L. Varicella/ Herpes Zoster. In: Control of Communicable Diseases Manual (20th ed.). Washington, DC: American Public Health Association. 2015. p. 669- 675.

Leduc D. Editor. Well Beings. A Guide to Health in Child Care. Third Edition (revised). Canadian Paediatric Society. 2015. Available at www.caringforkids.cps.ca/wellbeings/wellbeings_index

Lopez AS, Marin M. Strategies for the control and investigation of varicella outbreaks. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. 2008.

Available at www.cdc.gov/chickenpox/outbreaks/downloads/manual.pdf

MacDonald NE. School and daycare exclusion policies for chickenpox: A rational approach. Canadian Paediatric Society Position Statement. Paediatr Child Health. 1999;4(4):287-388 Addendum January 2008; Reaffirmed 2018. Available at

www.cps.ca/en/documents/position/exclusion-policies-for-chickenpox

Public Health Agency of Canada. Canadian Immunization Guide: Part 4 – Active Vaccines. Varicella (Chickenpox) Vaccine. Post-exposure immunization. Date modified Mar 13, 2018. Available at

www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-24-varicella-chickenpox-vaccine.html#p4c23t2

Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Varicella Proof of Immunity – 2015 Update. 2016 July:1-18.

Available at www.canada.ca/en/public-health/services/publications/healthy-living/varicella-proof-immunity-2015-update.html?_ga=2.32832376.715986700.1516642178-193489029.1494096035

Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Varicella Vaccination Two-Doses Recommendation. Canada Communicable Diseases Report. 2010;36 (ACS-8): 1-26. Available at

www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2010-36/canada-communicable-disease-report-13.html#pg7

Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Updated recommendations for the use of varicella zoster immune globulin (Varlg) for the prevention of varicella in at-risk patients. 2016 July:1-14. Available at

www.canada.ca/en/public-health/services/publications/healthy-living/updated-recommendations-use-varicella-zoster-immune-globulin-varig-prevention-varicella-risk-patients.html?_ga=2.268286536.715986700.1516642178-193489029.1494096035

Public Health Agency of Canada. (2009). Case Definitions for Communicable Diseases Under National Surveillance – 2009. Canada Communicable Disease Report. Volume 35S2. Available at

<http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s2/index-eng.php>

Yukon Immunization Guidelines (2018). Administration of Biological Products. Retrieved from

www.hss.gov.yk.ca/yipm.php



13.0 CONTACT INFORMATION

Yukon Communicable Disease Control

Hours: Monday- Friday (08:30 to 16:30)
#4 Hospital Road, Whitehorse, YT Y1A 3H8
Telephone:
Local (867) 667-8323
Within Yukon 1-800-661-0408, ext. 8323
Fax: (867) 667-8349

Dr. Brendan E. Hanley MD CCFP (EM) MPH

Chief Medical Officer of Health, Yukon
204 Lambert Street, 4th Floor, Whitehorse,
PO Box 2703 (H-2)
Telephone:
Office: (867) 456-6136
Cell: (867) 332-1160
Fax: (867) 667-8349

Whitehorse General Hospital

(Ambulatory Care)
#5 Hospital Road, Whitehorse, YT Y1A 3H7
Telephone: (867) 393-8700
Fax: (867) 393-8772
WGH Laboratory telephone: (867) 393-8739